Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | RAB9A | P51151 | 5/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 3/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.52 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222382 | 0.98 | PTPN1 (0.89) | PTPN1SMN1; SMN2ALDH1A1GAANPC1 | |
| Hydrochloric Acid SCHEMBL19118776 | 0.98 | PTPN1 (0.89) | PTPN1SMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL2329015 | 0.98 | PTPN1 (0.89) | PTPN1SMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL27790021 | 0.88 | PTPN1 (0.73) | PTPN1SMN1; SMN2ALDH1A1GAANPC1 | |
| Hydrochloric Acid SCHEMBL27933403 | 0.86 | PTPN1 (0.71) | PTPN1SMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL12831210 | 0.85 | PTPN1 (0.69) | PTPN1SMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL893125 | 0.85 | PTPN1 (0.69) | PTPN1SMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL3093950 | 0.85 | PTPN1 (0.69) | PTPN1SMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL8840165 | 0.83 | PTPN1 (0.72) | PTPN1SMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL19075480 | 0.83 | PTPN1 (0.72) | PTPN1SMN1; SMN2ALDH1A1GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919892-B1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2013-08-14 | — | — | EP | claimed |
| US-7842696-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-30 | — | — | US | claimed |
| US-20090221583-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-03 | — | — | US | claimed |
| WO-2008157844-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-12-24 | — | — | WO | claimed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | claimed |
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119192103-A | Five-membered heterocyclic amide compound, preparation method and application thereof, and bactericide | 贵州大学 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-11434212-B2 | Bicyclic compound as a caspase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-09-06 | — | — | US | disclosed |
| EP-3572402-B1 | LINKED CYCLIC COMPOUND AS CASPASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-05-04 | — | — | EP | disclosed |
| US-20210332019-A1 | Bicyclic Compound as a Caspase Inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| US-20050209284-A1 | Tec kinase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005079791-A1 | THIOPHENE -2- CARBOXYLIC ACID - (1H - BENZIMIDAZOL - 2 YL) - AMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE TEC KINASE ITK (INTERLEUKIN -2- INDUCIBLE T CELL KINASE) FOR THE TREATMENT OF INFLAMMATION, IMMUNOLOGICAL AND ALLERGIC DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005002673-A1 | RAF KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| US-5591695-A | Herbicidal [1,3,4]oxadiazoles and thiadiazoles | AMERICAN CYANAMID CO. (US) | 1997-01-07 | — | — | US | disclosed |
| CN-1134935-A | Herbicidal (1,3,4) oxadiazoles and thiadiazoles | AMERICAN CYANAMID CO (US) | 1996-11-06 | — | — | CN | disclosed |
| EP-0726263-A2 | Herbicidal (1,3,4)oxadiazoles and thiadiazoles | American Cyanamid Company (US) | 1996-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | MAPK1, MAPK3, MAPK10 | PTPN1 372/4885SMN1; SMN2 3407/4885ALDH1A1 3196/4885 |
| US-11434212-B2 | Bicyclic compound as a caspase inhibitor | CASP1, CASP14, CASP2 | PTPN1 4110/4885SMN1; SMN2 1738/4885ALDH1A1 3348/4885 |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | SI, CYP3A5, CYP2D6 | PTPN1 1371/4885SMN1; SMN2 1271/4885ALDH1A1 1081/4885 |
| US-20210332019-A1 | Bicyclic Compound as a Caspase Inhibitor | CASP1, CASP14, CASP2 | PTPN1 4110/4885SMN1; SMN2 1738/4885ALDH1A1 3348/4885 |
| US-20090221583-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | PTPN1 4580/4885SMN1; SMN2 4076/4885ALDH1A1 969/4885 |
| US-20050209284-A1 | Tec kinase inhibitors | TEC, ITK, TXK | PTPN1 961/4885SMN1; SMN2 3626/4885ALDH1A1 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.